介入治疗后ACS患者中医证候要素分布特征的现况调查

目的调查介入治疗后急性冠脉综合征（ACS）患者中医证候要素的分布规律。方法采用横断面研究设计．ACS患者于介人治疗成功后24—48h内调查其病史、症状、体征及证候要素特点，利用冠心病中医临床科研共享系统进行数据录入和管理．应用SPSS13．0进行统计分析。结果共调查5家医院480例介入治疗成功的ACS患者，其中血瘀占81．7％，痰浊偏寒占22．5％，痰浊偏热占18．3％，气虚占51．7％，阴虚占42．5％，阳虚占10．8％。证候要素组合情况显示：2个证候要素相兼占52．5％，3个证候要素相兼占23．3％，单证候要素占14．2％，4个证候要素占10．0％。其中血瘀与痰浊（包括偏寒与偏热）相兼占34．2％，血瘀与气虚相兼占44．2％，血瘀与阴虚相兼占32．5％．气虚与阴虚相兼占26．7％。结论介入治疗后ACS患者证候要素主要是血瘀、气虚，证候要素组合以2个证候要素组合最常见，其中以血瘀兼气虚组合最常见。

Distribution and Combination Characteristics of TCM Syndrome Elements in Acute Coronary Syndrome Patients with Percutaneous Coronary Intervention

Objective： To investigate the distribution and combination characteristics of TCM syndrome elements in acute coronary syndrome （ACS） patients with percutaneous coronary intervention （PCI）. Methods： The ACS cases diagnosed by coronary arteriongraphy in 24-48 hours were collected and made TCM syndrome elements differentiation based on medical history ,symptom and sign. The SPSS 13.0 software statistics was used in data analysis. Results： 480 ACS cases were involved. The asthenia in superficiality proportions of the disease nature of syndrome elements from high to low were as follows：blood stasis in 81.7%, cold turbid phlegm in 22.5%, heat turbid phlegm in 18.3%. The asthenia in origin proportions in the disease narure were：qi deficiency in 51.6% ,yin deficiency in 42.5%,yang deficiency in 10.8%.In the elments combination form： 2 disease nature elements combined occupied 52.5%. 3 disease nature elements combined was 23.3%. The single element account for 14.2%, the proportion of four disease nature elementscombined was 10.0%. In the specific combination,blood stasis and turbid phlegm including cold and heat accounted for 34.17% ,blood stasis and qi deficiency made up 44.17%, blood stasis and yin deficiency accounted for 32.5% ,qi and yin deficiency accounted for 26.67%. Conclusion： The main syndrome elments are blood stasis,qi deficiency. 2 syndrome elments combined is the most common, which blood stasis and qi deficiency take the largest proportion.